RAC

1.27%

$1.55 race oncology ltd

Ann: Race starts preclinical breast cancer study for Bisantrene, page-57

First 57 Last

Share
Profile

Follow
IndexInvestor

8,470 Posts.

1388

25/08/21

01:38

Post #: 55543532
Share

Originally posted by Mason14: ↑

There can be a little more added to this that @IndexInvestor should really have generously explained to you.

Zantrene was shown to be significantly more potent (between 2x and 5x) than other anthracyclines in MCF-7 breast cancer cells resistant to a number of different SoC drugs.

The MCF-7 cells used in this trial have been previously identified as breast cancer cells that have upregulated FTO (1,2).

MCF-7 cells that had been pre-treated with Doxorubicin lead to an upregulation of FTO (3). I speculate that pretreatment of the SoC drugs in the MCF-7 breast cancer cells may have upregulated cellular FTO, which is why Bisantrene was sensitive and the other anthracyclines were not (the upregulated FTO led to drug resistance).

Based on this data, I am very confident that the results observed in the most recently announced preclinical breast cancer results is a result of Zantrene inhibtiing FTO in these cell lines. An interesting thought provoker is the magnitude or scale of FTO upregulation being central to anti-cancer therapy resistance.

The preclinical breast cancer program is continuing, which I believe will include mouse models and drug combinations with a multi-billion dollar breast cancer drug like a HER-2 monoclonal (I think likely), or maybe even something like Trodelvy. There might be other possible and more likely drug combinations, but it's a bit late for me in Perth and that's all I can come up with.

1 https://www.spandidos-publications.com/10.3892/ol.2017.6038
2 https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-019-1004-4
3 https://www.tandfonline.com/doi/full/10.1080/21655979.2021.1924544

Expand

I hereby assure @Mason14 and all HC posters that the reason that I didn't post anything about MCF-7 lines and what the expanded scope of this preclinical may plausibly be is not out of any lack of generosity, but simply because I'm incapable of having written any part of it.

And it will take me some time to attempt to absorb what Mason has generously provided. Not now; it's a bit late for me in Sydney.

Buy, Held

Last edited by IndexInvestor: 25/08/21
33 Upvote

0 Great analysis

Reply

Top Stories

Emerald & Azure score Digger & Dealer awards

IMD

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

WNX

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

Bitcoin: Current State of Play & Where to Next | Swyftx

EQR

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

M2R

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

SVL

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

ARD

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

VTM

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

There are more pages in this discussion • 62 more messages in this thread...

First 57 Last

Add RAC (ASX) to my watchlist

(20min delay)
Last $1.55		Change -0.020(1.27%)		Mkt cap ! $264.0M

Open	High	Low	Value	Volume
$1.59	$1.62	$1.51	$218.3K	138.7K

Buyers (Bids)

No.	Vol.	Price($)
1	95	$1.53

Sellers (Offers)

Price($)	Vol.	No.
$1.55	157	1

View Market Depth

No.	Vol.	Price($)
3	29100	1.500
1	353	1.470
2	3444	1.440
3	101000	1.420
4	14785	1.400

Price($)	Vol.	No.
1.550	157	1
1.580	6715	2
1.600	2319	1
1.620	5327	1
1.630	1270	1

Last trade - 16.10pm 16/08/2024 (20 minute delay)

RAC (ASX) Chart

Ann: Race starts preclinical breast cancer study for Bisantrene, page-57

Emerald & Azure score Digger & Dealer awards

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

Bitcoin: Current State of Play & Where to Next | Swyftx

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Race starts preclinical breast cancer study for Bisantrene, page-57

Top Stories

Emerald & Azure score Digger & Dealer awards

IMDEX to receive $10M in out-of-court settlement with Boart Longyear over downhole tool patent

Wellnex sees first special access scheme prescriptions for new Wellness Life brand

Bitcoin: Current State of Play & Where to Next | Swyftx

EQ Resources transitions historic Mt Carbine tungsten mine to owner-operator system

EIS co-funded campaign sees Miramar kick off maiden drilling at Bangemall, Gascoyne WA

Week 33 Wrap: US recession fears forgotten; RBNZ’s surprise rate cut; more iron ore trouble

Court of Appeal upholds environmental group's challenge to Silver Mines Ltd's Bowden project

Argent begins search for VMS mineralisation at Kempfield Cu-Pb-Zn-Au-Ag play in NSW

Victory Metals dips -8% even as company set to grow heavy REE resource at North Stanmore

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News